DRGT 65

Drug Profile

DRGT 65

Alternative Names: DRGT-65

Latest Information Update: 26 Jul 2016

Price : $50

At a glance

  • Originator Druggability Technologies
  • Class Antipsychotics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Psychotic disorders

Highest Development Phases

  • Phase I Bipolar depression; Schizophrenia

Most Recent Events

  • 26 Jul 2016 DRGT 65 is available for licensing as of 26 Jul 2016. http://www.drgtco.com/partnering/
  • 25 Jul 2016 Phase-I clinical trials in Bipolar depression in Ireland (unspecified route) prior to July 2016 (Druggability pipeline, July 2016)
  • 25 Jul 2016 Phase-I clinical trials in Schizophrenia in Ireland (unspecified route) prior to July 2016 (Druggability pipeline, July 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top